MG-115 (CAS 133407-86-0)

MG-115 is a potent, reversible proteasome inhibitor. MG-115 specifically inhibits the chymotrypsin-like activity of the proteasome. MG-115 is an inhibitor of 20S Proteasome and 26S Proteasome. It has been shown to induce apoptosis in Rat-1 and PC12 cells via a p53-dependent pathway. The ubiquitin-proteasome system (UPS) and autophagy serve as two complementary, reciprocally regulated protein degradation systems, thus blockade of UPS by MG-115 activates autophagy.

References

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex: A. Vinitsky, et al.; Biochemistry 31, 9421 (1992) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B: V.J. Palombella, et al.; Cell 78, 773 (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules: K.L. Rock, et al.; Cell 78, 761 (1994) Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae: D.H. Lee & A.L. Goldberg; J. Biol. Chem. 271, 27280 (1996) p53-dependent induction of apoptosis by proteasome inhibitors: U.G. Lopes, et al.; J. Biol. Chem. 272, 12893 (1997) Proteasome inhibition results in increased poly-ADP-ribosylation: implications for neuron death: J.N. Keller & W.R. Markesbery; J. Neurosci. Res. 61, 436 (2000) Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression: L. Salmena, et al.; Biochem. Pharmacol. 61, 795 (2001)